Andri Sanityoso Sulaiman

Dr. Andri Sanityoso Sulaiman

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2010 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
IBIndra Bachtiar
Indra Bachtiar
VKValentine Kheng
Valentine Kheng
GWGunawan A Wibowo
Gunawan A Wibowo
RGRino A Gani
Rino A Gani
IHIrsan Hasan
Irsan Hasan
STSusan Tai
Susan Tai
The outcome of patients with hepatocellular carcinoma (HCC) remains poor because of late diagnosis. We determined the performances of α -1-acid glycoprotein (AAG) and des-γ-carboxy prothrombin (DCP) for the diagnosis of HCC, especially for α-fetoprotein (AFP)-low HCC.

20 March 2019 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YFYoga Fitriakusumah
Yoga Fitriakusumah
CLCosmas Rinaldi Adithya Lesmana
Cosmas Rinaldi Adithya Lesmana
WBWinda Permata Bastian
Winda Permata Bastian
CJChyntia Olivia Maurine Jasirwan
Chyntia Olivia Maurine Jasirwan
IHIrsan Hasan
Irsan Hasan
RGRino A. Gani
Rino A. Gani
Non-alcoholic fatty liver disease (NAFLD) is an emerging disease, where it can progress to non-alcoholic steatohepatitis (NASH) and lead to liver cirrhosis or liver cancer. Small intestinal bacterial overgrowth (SIBO) has been hypothesized to play an important role in NAFLD development and progression, however, there is still conflicting data about this phenomenon. Transient Elastography (TE) examination using controlled attenuation parameter (CAP) has been validated for liver disease progression assessment in NAFLD. It is non-invasive method and easy to perform in clinical practice. Therefore, we would like to know the role of SIBO in NAFLD and its possible impact on disease progression. A cross-sectional design study performed at outpatient’s Hepatobiliary clinic at tertiary referral university hospital in Jakarta. All recruited study subjects based on inclusions criteria underwent laboratory examination, transabdominal ultrasound examination, CAP-TE 502 (by Echosens, France), and glucose hydrogen breath test (GHBT) using portable hydrogen breath test apparatus (Gastro+™ Gastrolyzer by Bedfont Scientific Ltd). Stool sample examination was performed using RT-PCR. This study recruited 160 subjects with median age of 58 (22–78) years and 108 (67.5%) of them are female. SIBO (65,5%), DM (70.8%), dyslipidemia (75.2%), obesity (76.6%), and metabolic syndrome (73%) were more prevalent in NAFLD than non-NAFLD population. Bivariate analysis showed no significant association between SIBO and NAFLD development (p = 0.191; PR 0.871; CI 95% [0.306–1.269]). SIBO was also not associated with significant hepatic steatosis (p = 0.951; PR = 0.951; CI 95% [0.452–2.239]) and fibrosis (p = 0.371; PR = 1.369; CI 95% [0.608–3.772]). However, the presence of central obesity has significantly associated with the presence of SIBO (p = 0.001; PR = 0.378; CI 95% [0.021–0.478]). Based on stool sample analysis from 60 NAFLD patients, there is a significant correlation using Spearmen test between the presence of Bacteroides and the stage of fibrosis (p .037). Further analysis between obese NAFLD patients and non-obese NAFLD patients showing that there is a significant decrease of Bifidobacteria (p .047) and Lactobacillus (p .038) in obese NAFLD patients and a tendency of increase Bacteroides in obese NAFLD patients (p .572). SIBO is not associated with NAFLD development and progression.

15 February 2023 in Hepatology International
Verified
Journal Article
Closed access
PDF file
SSSanchit Sharma
Sanchit Sharma
SASamagra Agarwal
Samagra Agarwal
ASAnoop Saraya
Anoop Saraya
ACAshok Choudhury
Ashok Choudhury
SSSanjiv Saigal
Sanjiv Saigal
APAPASL ACLF Research Consortium (AARC) for APASL ACLF working party
APASL ACLF Research Consortium (AARC) for APASL ACLF working party

28 July 2022 in JGH Open
Verified
Journal Article
Open access
RPRabbinu Rangga Pribadi
Rabbinu Rangga Pribadi
MSMarcellus Simadibrata
Marcellus Simadibrata
ASAndri Sanityoso Sulaiman
Andri Sanityoso Sulaiman
MAMurdani Abdullah
Murdani Abdullah
Background and Aim: Sarcopenia is a problem affecting inflammatory bowel disease (IBD) outcome and should be evaluated by measuring muscle mass (using dual‐energy X‐ray absorptiometry [DXA]), muscle strength, and physical performance. DXA has drawbacks as it is expensive, not covered by a national program, and requires a technician. Other inexpensive and simple examinations are needed. The objective is to explore cutoff point and diagnostic accuracy of thigh circumference (TC), calf circumference (CC), subjective global assessment (SGA), and handgrip strength (HGS) to identify sarcopenia in IBD patients.Methods: The study was conducted in Cipto Mangunkusumo Hospital during November 2020–June 2021. Analysis was performed to discover the cutoff point and diagnostic accuracy of TC, CC, SGA, and HGS to identify sarcopenia.Results: As assessed by DXA, 7 of 60 women (11.7%) with IBD had sarcopenia. Using CC cutoff ≤31 cm, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ration (PLR), and negative likelihood ratio (NLR) were 100%, 60.38%, 25%, 100%, 2.52, and 0, respectively. Using TC cutoff ≤50 cm, the sensitivity, specificity, PPV, NPV, PLR, and NLR were 100%, 83.02%, 43.75%, 100%, 5.90, and 0, respectively. SGA has sensitivity, specificity, PPV, NPV, PLR, and NLR of 42.86%, 84.91%, 27.27%, 91.84%, 2.84, and 0.67, respectively. The area under curve of HGS was 33.3%.Conclusion: In this survey of Indonesian women with IBD, the frequency of sarcopenia was 11.7%. When compared with DXA, TC and CC values over 50 cm and 31 cm, respectively, were helpful to exclude the diagnosis of sarcopenia. SGA and HGS were of lesser value for the identification of a decrease in muscle mass.

1 October 2022
Verified
Journal Article
Closed access
ASAndri Sanityoso Sulaiman
Andri Sanityoso Sulaiman
IHIrsan Hasan
Irsan Hasan
CLCosmas Rinaldi A. Lesmana
Cosmas Rinaldi A. Lesmana
JKJuferdy Kurniawan
Juferdy Kurniawan
CJChyntia Olivia Maurine Jasirwan
Chyntia Olivia Maurine Jasirwan
RGRino Alvani Gani
Rino Alvani Gani

30 September 2023 in Jurnal Penyakit Dalam Indonesia
Verified
Journal Article
Open access
PDF file
DHDepartemen Ilmu Penyakit Dalam Divisi Hepatobilier
Departemen Ilmu Penyakit Dalam Divisi Hepatobilier
ASAndri Sanityoso Sulaiman
Andri Sanityoso Sulaiman
Introduction. Prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing throughout the world due to sedentary lifestyle and dietary habit, including in patients with chronic hepatitis B (CHB). In several studies, advanced of liver disease were more likely observed among those CHB patients with NAFLD. NAFLD might increase the risk of liver disease progression in CHB patients, but prior investigations were still limited. This study aimed to determine the association between NAFLD and risk of liver fibrosis in CHB patients. Methods. All patients with positive serum hepatitis B surface antigen in the Hepatobilier Data Registry, Cipto Mangunkusumo Hospital, were included in this study. Based on abdominal ultrasonography, patients were divided into two group (group I: non-NAFLD – hepatitis B patients vs. group II: NAFLD – hepatitis B patients). Data demographic and clinical examination were collected. Significant liver fibrosis was defined as stage liver fibrosis above 7 kPa (≥ F2). Logistic regression was used to identify NAFLD as risk factor for significant fibrosis. Variables were expressed as prevalence odd ratio (POR) with 95% CI. P values <0.05 were considered statistically significant. Results. Among 130 hepatitis B patients, 45 patients (34.6%) were diagnosed with NAFLD. Of 45 patients in group II, 36 patients (80%) had significant liver fibrosis. It was observed that a higher percentage of patients in group II were HBeAg negative compared to those in group I (66.7% vs. 35.9%; p=0.038). Furthermore, group II also displayed higher levels of liver stiffness compared to group I (12.22 (8.6 kPa) vs. 8.57 (7.8 kPa); p 0.016). In multivariate analysis, NAFLD was significantly associated with significant liver fibrosis (POR: 5.87; CI95%: 2.48 – 13.86; p < 0.001) after adjusted with HBeAg status. Conclusion. NAFLD associated with the higher risk of liver fibrosis in patients with hepatitis B. Modification of lifestyle and potential therapeutic intervention may help in reducing the progression of liver fibrosis.